Literature DB >> 26766592

An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma.

A Ari Hakimi, Ed Reznik, Chung-Han Lee, Chad J Creighton, A Rose Brannon, Augustin Luna, B Arman Aksoy, Eric Minwei Liu, Ronglai Shen, William Lee, Yang Chen, Steve M Stirdivant, Paul Russo, Ying Bei Chen, Satish K Tickoo, Victor E Reuter, Emily H Cheng, Chris Sander, James J Hsieh.   

Abstract

Dysregulated metabolism is a hallmark of cancer, manifested through alterations in metabolites. We performed metabolomic profiling on 138 matched clear cell renal cell carcinoma (ccRCC)/normal tissue pairs and found that ccRCC is characterized by broad shifts in central carbon metabolism, one-carbon metabolism, and antioxidant response. Tumor progression and metastasis were associated with metabolite increases in glutathione and cysteine/methionine metabolism pathways. We develop an analytic pipeline and visualization tool (metabolograms) to bridge the gap between TCGA transcriptomic profiling and our metabolomic data, which enables us to assemble an integrated pathway-level metabolic atlas and to demonstrate discordance between transcriptome and metabolome. Lastly, expression profiling was performed on a high-glutathione cluster, which corresponds to a poor-survival subgroup in the ccRCC TCGA cohort.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26766592      PMCID: PMC4809063          DOI: 10.1016/j.ccell.2015.12.004

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  51 in total

Review 1.  Mitochondrial tumour suppressors: a genetic and biochemical update.

Authors:  Eyal Gottlieb; Ian P M Tomlinson
Journal:  Nat Rev Cancer       Date:  2005-11       Impact factor: 60.716

Review 2.  Regulation of hepatic glutathione synthesis: current concepts and controversies.

Authors:  S C Lu
Journal:  FASEB J       Date:  1999-07       Impact factor: 5.191

3.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Authors:  Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

Review 4.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.

Authors:  Ralph J DeBerardinis; Julian J Lum; Georgia Hatzivassiliou; Craig B Thompson
Journal:  Cell Metab       Date:  2008-01       Impact factor: 27.287

Review 5.  Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases.

Authors:  Robert A Casero; Laurence J Marton
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

Review 6.  The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2008-10-16       Impact factor: 60.716

Review 7.  Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

Authors:  Dunyaporn Trachootham; Jerome Alexandre; Peng Huang
Journal:  Nat Rev Drug Discov       Date:  2009-05-29       Impact factor: 84.694

8.  Cancer cell metabolism: Warburg and beyond.

Authors:  Peggy P Hsu; David M Sabatini
Journal:  Cell       Date:  2008-09-05       Impact factor: 41.582

Review 9.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

Review 10.  HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation.

Authors:  John D Gordan; Craig B Thompson; M Celeste Simon
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

View more
  191 in total

1.  Kidney cancer: When worlds collide--integrating metabolic and transcriptomic data in ccRCC.

Authors:  Clemens Thoma
Journal:  Nat Rev Urol       Date:  2016-01-27       Impact factor: 14.432

2.  Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.

Authors:  Omran Abu Aboud; Ching-Hsien Chen; William Senapedis; Erkan Baloglu; Christian Argueta; Robert H Weiss
Journal:  Mol Cancer Ther       Date:  2016-07-07       Impact factor: 6.261

3.  Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery.

Authors:  David F McDermott; Michael Carducci
Journal:  J Clin Oncol       Date:  2018-10-29       Impact factor: 44.544

Review 4.  Understanding the Intersections between Metabolism and Cancer Biology.

Authors:  Matthew G Vander Heiden; Ralph J DeBerardinis
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

5.  Volatile metabolomic signature of bladder cancer cell lines based on gas chromatography-mass spectrometry.

Authors:  Daniela Rodrigues; Joana Pinto; Ana Margarida Araújo; Sara Monteiro-Reis; Carmen Jerónimo; Rui Henrique; Maria de Lourdes Bastos; Paula Guedes de Pinho; Márcia Carvalho
Journal:  Metabolomics       Date:  2018-04-17       Impact factor: 4.290

6.  Gamma-Glutamyltransferase 1 Promotes Clear Cell Renal Cell Carcinoma Initiation and Progression.

Authors:  Ankita Bansal; Danielle J Sanchez; Vivek Nimgaonkar; David Sanchez; Romain Riscal; Nicolas Skuli; M Celeste Simon
Journal:  Mol Cancer Res       Date:  2019-05-31       Impact factor: 5.852

7.  A Landscape of Metabolic Variation across Tumor Types.

Authors:  Ed Reznik; Augustin Luna; Bülent Arman Aksoy; Eric Minwei Liu; Konnor La; Irina Ostrovnaya; Chad J Creighton; A Ari Hakimi; Chris Sander
Journal:  Cell Syst       Date:  2018-01-27       Impact factor: 10.304

8.  Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity.

Authors:  Joshua D Ochocki; Sanika Khare; Markus Hess; Daniel Ackerman; Bo Qiu; Jennie I Daisak; Andrew J Worth; Nan Lin; Pearl Lee; Hong Xie; Bo Li; Bradley Wubbenhorst; Tobi G Maguire; Katherine L Nathanson; James C Alwine; Ian A Blair; Itzhak Nissim; Brian Keith; M Celeste Simon
Journal:  Cell Metab       Date:  2018-05-10       Impact factor: 27.287

9.  Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.

Authors:  James J Hsieh; David Chen; Patricia I Wang; Mahtab Marker; Almedina Redzematovic; Ying-Bei Chen; S Duygu Selcuklu; Nils Weinhold; Nancy Bouvier; Kety H Huberman; Umesh Bhanot; Michael S Chevinsky; Parul Patel; Patrizia Pinciroli; Helen H Won; Daoqi You; Agnes Viale; William Lee; A Ari Hakimi; Michael F Berger; Nicholas D Socci; Emily H Cheng; Jennifer Knox; Martin H Voss; Maurizio Voi; Robert J Motzer
Journal:  Eur Urol       Date:  2016-10-15       Impact factor: 20.096

10.  Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.

Authors:  Lin Li; Weili Miao; Ming Huang; Preston Williams; Yinsheng Wang
Journal:  Mol Cell Proteomics       Date:  2018-11-28       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.